Advisers to the U.S. Food and Drug Administration on Thursday will discuss and vote on whether to recommend targeting one of the currently dominant XBB coronavirus variants in updated COVID-19 shots being developed for a fall vaccination campaign.
Tag Archive for: Moderna
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Adding an experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported today.
Its establishment of a mainland China unit comes as its revenue growth slows sharply due to waning global demand for its COVID-19 vaccine, the U.S. company’s only approved product.
Moderna Inc. on Thursday reported a surprise profit and stronger-than-expected sales for its COVID-19 vaccine in the first quarter, as it received payments for orders that were deferred last year.
The U.S. Food and Drug Administration has approved GSK Plc’s respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
The World Health Organization officially launched its mRNA vaccine technology hub in Cape Town, a facility established during the COVID-19 pandemic to help poorer countries struggling to gain access to life-saving medication.
The U.S. Food and Drug Administration on Tuesday authorized a second dose of Omicron-targeting COVID-19 vaccines for older adults as well as those with a weak immune system.
As the COVID pandemic continues, Moderna wants to show that its mRNA technology can treat more than just COVID, and has launched a video spot, “Welcome to the mRNAge,” that will appear online, on TV, and elsewhere.
A U.S. appeals court handed Moderna Inc. a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp. patent related to the companies’ legal fight over Moderna’s blockbuster COVID-19 vaccines.
